

\$280.84 \$1.00 (0.36%) as of Friday's closeCap (\$M USD)
\$150,868P/E
37.2EPS (1Y)
8.0%Dividend
\$9.52Last Filing
12/31/24

52-wk Range

\$253.30  \$346.85Sales (\$M)
33,424Fwd. P/E
13.1Sales (1Y)
13.2%Fwd. Yield
3.4%Next Earnings
05/01/25**Dividend Adjusted Return** Apr 25, 2024 - Apr 25, 2025**AMGN 280.84 (+6.0%) Healthcare 251.47 (-0.8%) S&P 500 5525.21 (+10.3%)**


AMGN has underperformed the S&P 500 by -4.3% in the past year.


AMGN has outperformed its sector by 6.8% in the past year.


The Healthcare sector has underperformed the market by -11.1% in the past year.


ANALYST CONSENSUS**Buy**


The consensus rating has worsened a little since last month when it was also Buy.




Strong Buy  13

Buy  1

Hold  13

Sell  1

Strong Sell  2

QUANTITATIVE SCORES**Fair Value** \$363.05**Margin of Safety** 29%

The Margin of Safety is the difference between a company's Fair Value and the current price. See more on page 8.

 **2 warnings** 

Details on Page 8

Value Score**78****Value Score:** Our value score looks at EV/EBITDA, P/E, P/S, P/TB (Price/Tangible Book) and EPS Predictability. P/S and P/TB are compared within a sector. Other metrics are compared across all stocks**Quality Score****77****Quality Score:** Our quality score compares profitability and balance sheet metrics to find high quality companies using ROIC, Net Margin, Gross Margin, Interest Coverage, and Debt / Equity metrics.**Growth Score****88****Growth Score:** Our growth score looks at the 5 year history and the forward estimates for EBITDA, Sales, and EPS growth, ranking the best companies across all stocks.**Sentiment Score****52****Sentiment Score:** Our sentiment score finds stocks in favor by analyzing Short Interest, returns in key periods over the last year, Price vs. 52-wk High, Days Since 52-wk High and MACD signals.**BUSINESS SUMMARY**

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.


Employees 28,000**Homepage** www.amgen.com**Headquarters** Thousand Oaks, CA

VALUATION SUMMARY

	AMGN	Industry	S&P 500
Value Score	78	67	70
Price / Earnings	37.2	26.2	26.4
Price / Sales	4.6	4.2	2.9
Price / Free Cash Flow	14.6	21.4	31.6
Price / Book	25.6	5.6	4.9
Price / Tangible Book	-	-	500+
EV / EBITDA	14.9	21.6	20.8
EPS Predict. Pctl.	82	72	70
Piotroski F Score	6	6	7
5-Year P/E Range	14.9		56.6
5-Year P/B Range	11.7		148.6
5-Year P/S Range	4.2		6.5


GROWTH SUMMARY


	AMGN	Industry	S&P 500
Growth Score	88	74	77
Sales Growth			
Sales Growth Next Year	2.3%	8.1%	9.9%
Sales 1-Year Chg (%)	13.2%	8.9%	12.3%
Sales 3-Year Avg (%)	8.3%	-2.1%	7.8%
Sales 5-Year Avg (%)	6.9%	2.8%	11.4%
EPS Growth			
Next Yr. Growth Est.	4.2%	19.2%	14.3%
EPS 1-Year Chg (%)	8.0%	48.4%	12.2%
EPS 3-Year Avg (%)	-9.3%	0.1%	8.6%
EPS 5-Year Avg (%)	-9.9%	2.3%	13.3%


PEERS ANALYSIS SUMMARY

Ticker	Company	Cap (\$M USD)	P/E	Fwd. Yield	1M Return	1Y Return	Margin of Safety	Value Score	Growth Score	Quality Score
JNJ	Johnson & Johnson	\$371,930	17.2	3.4%	-4.0%	8.7%	6%	79	76	96
ABBV	AbbVie	\$329,136	78.1	3.5%	-6.7%	15.3%	8%	65	81	74
NVS	Novartis	\$220,832	19.1	3.6%	1.6%	17.3%	2%	82	77	96
AZN	AstraZeneca	\$216,484	31.0	2.2%	-4.8%	-5.4%	11%	63	95	92
MRK	Merck & Co	\$208,206	12.0	3.9%	-5.8%	-34.8%	29%	84	92	97
AMGN	Amgen	\$150,868	37.2	3.4%	-8.5%	7.4%	29%	78	88	77
PFE	Pfizer	\$129,989	16.3	7.5%	-10.3%	-3.6%	40%	82	61	81
GILD	Gilead Sciences	\$128,615	21.7	3.1%	-4.4%	64.0%	8%	75	76	61
SNY	Sanofi	\$126,292	18.5	4.2%	-5.6%	10.5%	23%	84	91	88
BMJ	Bristol-Myers Squibb	\$97,465	17.9	5.2%	-18.2%	12.4%	44%	85	62	83
TAK	Takeda Pharmace...	\$47,013	33.2	4.3%	-0.1%	17.6%	15%	80	77	69
BIIB	Biogen	\$17,395	10.6	-	-14.6%	-41.3%	46%	95	59	91

PROFITABILITY SUMMARY

	AMGN	Industry	S&P 500
Quality Score	77	78	78
Gross Margin	61.5%	72.1%	31.5%
Operating Margin	21.7%	23.9%	15.1%
Net Margin	12.2%	15.3%	11.1%
Return on Assets	4.3%	9.3%	10.5%
Return on Equity	69.6%	30.8%	33.9%
ROIC	10.1%	18.9%	24.9%



RETURNS SUMMARY

	AMGN	Industry	S&P 500
Sentiment Score	52	57	67
5-Day Return	1.3%	4.0%	4.6%
1-Month Return	-8.5%	-3.1%	-4.4%
YTD Return	8.6%	5.2%	-5.8%
1-Year Return	7.4%	3.0%	10.8%
3-Year Return	22.4%	15.7%	34.4%
5-Year Return	38.6%	42.1%	109.5%
Beta 1-Year	0.48	0.35	1.00

Dividend Adjusted Return Apr 25, 2024 - Apr 25, 2025

AMGN 282.19 (+5.8%)




DIVIDEND

	AMGN	Industr
Forward Dividend Yield	3.4%	2.8%
Payout Ratio	118.1%	68.2%
TTM Yield	3.3%	
Fwd. Div. Per Share	\$9.52	\$4.2
Div. 1Y Chg (%)	5.8%	9.5%
Div. 3Y Avg (%)	7.1%	5.4%
Div. 5Y Avg (%)	8.3%	6.0%
Cons. Growth Years	10+	
Div. Coverage Ratio	0.8	1.

DEBT & EQUITY

Current Ratio	1.3
Quick Ratio	1.0
Price	\$280.84
Net Cash Per Share	-\$89.78
Equity Per Share	\$10.94
Debt / Equity	10.2
Solvency Ratio	12%
Interest Coverage	2.5
Short % of Float	2.6%
Altman Z-Score	1.3

Debt / Equity 10.2



ANALYST REVISIONS

Current Quarter EPS		Next Quarter EPS	
# Up Last 30 days	1.00	# Up Last 30 days	3.00
# Down Last 30 days	8.00	# Down Last 30 days	7.00
Mean Estimate	4.27	Mean Estimate	5.31
% Change (30 Days)	-0.55%	% Change (30 Days)	-0.62%

MEAN ESTIMATE TREND

	Cur Qtr	Next Qtr	Cur Year	Next Year
Latest	\$4.27	\$5.31	\$20.61	\$21.49
30 Days Ago	\$4.30	\$5.34	\$20.64	\$21.56
90 Days Ago	\$4.81	\$5.35	\$20.79	\$21.23
% Change (90 Days)	-11.2%	-0.7%	-0.8%	1.2%

EARNINGS SURPRISES

Earnings surprise is the difference between a company's announced earnings and the average analyst estimated value. Surprises typically causes the stock price to jump and are often followed by more of the same surprise type.

Surprise Summary (Last 12 Quarters)		
Surprise Type	Amount	Percent
Positive Quarters (> 2%)	10	83.3%
Negative Quarters (< 2%)	0	-
In-Line Quarters (within 2%)	2	16.7%


Surprise Detail (Last 6 Quarters)

Surprise Type	Announce Date	Period End Date	Actual EPS	Est. EPS	Surprise (%)
Positive	02/04/25	12/31/24	\$5.31	\$5.08	4.5%
Positive	10/30/24	09/30/24	\$5.58	\$5.11	9.2%
In-Line	08/06/24	06/30/24	\$4.97	\$5.01	-0.8%
Positive	05/02/24	-	\$3.96	\$3.87	2.3%
Positive	02/06/24	-	\$4.71	\$4.61	2.2%
Positive	10/31/23	-	\$4.96	\$4.67	6.2%

RISK


	AMGN	Industry	S&P 500
Best Monthly Return (5Y)	20.9%	11.1%	17.9%
Worst Monthly Return (5Y)	-15.6%	-8.0%	-9.6%
Beta 1-Year	0.48	0.35	1.00
Volatility 1-Year	0.27	0.16	0.19
Volatility 1Y Pctl.	25	-	-
Max Drawdown 1-Year	-22.7%	-27.6%	-18.7%
Max Drawdown 3-Year	-24.9%	-32.4%	-18.7%
Max Drawdown 5-Year	-24.9%	-33.9%	-24.6%

AMGN Volatility 1-Year 0.3



SEASONALITY

Seasonal Performance vs the S&P 500



5-YEAR RELATIVE PERFORMANCE VS S&P 500

Relative to the S&P 500 baseline, AMGN has underperformed the S&P 500 by -71.6% in the past 5 Years.

AMGN has underperformed its sector by -3.6% in the past 5 Years.

The Healthcare sector has underperformed the market by -68.0% in the past 5 Years.

Dividend Adjusted Return Apr 24, 2020 - Apr 25, 2025



Overall Rating
vs. Peers






58

Ratings scores are relative to industry groups. They compare key metrics to rank stocks vs. their competitors.
For example, higher growth than peers will score high even when the absolute growth is below the market average.











Growth vs Peers

Ticker	Company	Growth Rating vs. Peer	Sales QoQ Chg.	Eps QoQ Chg.	Sales Growth Next Y.	Sales 1Y Chg (%)	Sales 3Y Avg (%)	Sales 5Y Avg (%)
GILD	Gilead Sciences	90	6.4%	24.6%	3.8%	4.8%	1.5%	4.8%
BMJ	Bristol-Myers Squibb	81	-5.6%	-	-6.4%	4.6%	0.5%	9.0%
SNY	Sanofi	76	9.1%	76.9%	6.8%	11.6%	3.8%	3.4%
AMGN	Amgen	74	10.9%	-18.3%	2.3%	13.2%	8.3%	6.9%
PFE	Pfizer	61	21.9%	-	-0.5%	15.9%	-11.7%	4.7%

Valuation vs Peers

Ticker	Company	Valuation Rating vs. Peer	P/E	Fwd. P/E	PEG Trailing	P/S	P/B	5Y P/E Range
SNY	Sanofi	88	18.5	10.3	1.4	2.6	1.5	8.3  41.1
PFE	Pfizer	84	16.3	7.6	-	2.1	1.5	6.3  -
BMJ	Bristol-Myers Squibb	80	17.9	7.9	0.5	2.0	5.6	12.2  -
GILD	Gilead Sciences	22	21.7	12.3	-	4.5	6.7	9.9  -
AMGN	Amgen	9	37.2	13.1	-	4.6	25.6	14.9  56.6

Efficiency vs Peers

Ticker	Company	Efficiency Rating vs. Peer	Gross Margin	Operating Margin	Net Margin	5Y ROE Range	5Y ROA Range
BMJ	Bristol-Myers Squ...	89	70.5%	16.5%	11.4%	-54.8%  31.2%	-9.5%  8.4%
AMGN	Amgen	74	61.5%	21.7%	12.2%	52.8%  624.8%	3.4%  12.3%
SNY	Sanofi	74	70.9%	22.2%	14.0%	2.9%  9.2%	-0.4%  6.6%
PFE	Pfizer	66	71.9%	23.5%	12.6%	-3.0%  33.6%	-1.2%  16.6%
GILD	Gilead Sciences	61	78.3%	36.5%	1.7%	-1.4%  34.4%	-0.4%  11.3%

Financial Strength vs Peers

Ticker	Company	Financial Str. Rating vs. Peers	Debt / Equity	Interest Coverage	Quick Ratio	Intangibles %	Solvency Ratio	Short % of Float
GILD	Gilead Sciences	81	1.4	1.7	1.5	47.9%	9%	1.7%
SNY	Sanofi	61	0.3	15.9	0.7	48.4%	14%	0.2%
PFE	Pfizer	57	0.7	3.6	0.9	58.1%	15%	1.7%
BMJ	Bristol-Myers Squibb	54	3.0	4.0	1.2	48.2%	19%	1.5%
AMGN	Amgen	51	10.2	2.5	1.0	50.5%	12%	2.6%


Dividends vs Peers

Ticker	Company	Dividends Rating vs. Peer	Fwd. Yield	TTM Yield	Price	Fwd. Div. Per Share	Consecutive Div. Growth Years	Payout Ratio
PFE	Pfizer	89	7.5%	7.4%	\$22.92	\$1.72	10+	118.3%
BMJ	Bristol-Myers Squibb	80	5.2%	5.1%	\$47.90	\$2.48	3	90.7%
AMGN	Amgen	64	3.4%	3.3%	\$280.84	\$9.52	10+	118.1%
SNY	Sanofi	61	4.2%	3.9%	\$52.32	\$2.21	2	72.3%
GILD	Gilead Sciences	20	3.1%	3.0%	\$103.17	\$3.16	9	810.5%

Momentum vs Peers

Ticker	Company	Momentum Rating vs. Peer	1M Return	3M Return	6M Return	YTD Return	1Y Return	Beta 1Y	Volatility 1Y	Price vs 52-wk High (%)
GILD	Gilead Sciences	86	-4.4%	11.6%	17.7%	12.5%	64.0%	0.24	0.24	86.0%
SNY	Sanofi	64	-5.6%	-0.3%	-3.7%	8.5%	10.5%	0.23	0.23	87.0%
AMGN	Amgen	56	-8.5%	2.8%	-10.0%	8.6%	7.4%	0.48	0.27	81.0%
BMJ	Bristol-Myers Squibb	39	-18.2%	-18.9%	-5.7%	-13.4%	12.4%	0.18	0.29	75.6%
PFE	Pfizer	35	-10.3%	-12.2%	-16.8%	-12.2%	-3.6%	0.37	0.23	72.7%

DIVIDEND DETAIL



CALENDAR YEAR DIVIDEND HISTORY

Year	Ex-Dividend	Pay Date	Text	Amount
2025 Dividends				\$4.76
	05/16/25	06/06/25	Regular	\$2.38
	02/14/25	03/07/25	Regular	\$2.38
2024 Dividends				\$9.00
	11/18/24	12/09/24	Regular	\$2.25
	08/16/24	09/06/24	Regular	\$2.25
	05/16/24	06/07/24	Regular	\$2.25
	02/15/24	03/07/24	Regular	\$2.25
2023 Dividends				\$8.52
	11/16/23	12/08/23	Regular	\$2.13
	08/17/23	09/08/23	Regular	\$2.13
	05/17/23	06/08/23	Regular	\$2.13
	02/14/23	03/08/23	Regular	\$2.13
2022 Dividends				\$7.76
	11/16/22	12/08/22	Regular	\$1.94
	08/17/22	09/08/22	Regular	\$1.94
	05/16/22	06/08/22	Regular	\$1.94
	02/14/22	03/08/22	Regular	\$1.94
2021 Dividends				\$7.04
	11/15/21	12/08/21	Regular	\$1.76
	08/16/21	09/08/21	Regular	\$1.76
	05/14/21	06/08/21	Regular	\$1.76
	02/11/21	03/08/21	Regular	\$1.76
2020 Dividends				\$6.40

UPCOMING DIVIDEND

Ex-Dividend Date	05/16/25
Payment Date	06/06/25
Amount	\$2.38
Type	Regular

DIVIDEND RATE

Regular Dividend	\$2.38
Forward Dividend Rate	\$9.52
Forward Dividend Yield	3.4%
Trailing 12 Months Dividends	\$9.13
Trailing 12 Months Yield	3.3%

STATISTICS

Payout Ratio	118.1
Dividend Coverage Ratio	0.8
Consecutive Growth Years	10+
3 Year Growth Rate	7.1%
5 Year Growth Rate	8.3%
10 Year Growth Rate	11.7%


FINANCIAL STATEMENT SUMMARY

USD in Millions	Chart	2020	2021	2022	2023	2024	TTM	CAGR
Income Statement								
Revenue		25,424	25,979	26,323	28,190	33,424	33,424	6.5%
Operating Income		9,139	9,144	9,566	7,897	7,258	7,258	-5.2%
Net income		7,264	5,893	6,552	6,717	4,090	4,090	-12.5%
Earnings per share diluted		\$12.31	\$10.28	\$12.11	\$12.49	\$7.56	\$7.56	-10.7%
Average shares diluted		590	573	541	538	541	541	-2.0%
P/E Ratio		18.5	23.2	21.1	20.5	34.5	37.2	17.5%
Balance Sheet								
Cash		10,647	8,037	9,305	10,944	11,973	11,973	2.8%
Current assets		21,144	19,385	22,186	30,332	29,030	29,030	7.6%
Net Property, Plant and Equipm...		4,889	5,184	5,427	5,941	6,543	6,543	7.0%
Working Capital		9,491	7,201	6,499	11,940	5,931	5,931	-10.3%
Net Debt		22,339	25,272	29,640	53,669	48,126	48,126	19.5%
Stockholders' Equity		9,409	6,700	3,661	6,232	5,877	5,877	-10.3%
Cash Flow								
Operating Cash Flow		10,497	9,261	9,721	8,471	11,490	11,490	2.1%
Cap Ex		-608	-880	-936	-1,112	-1,096	-1,096	14.6%
Free Cash Flow		9,889	8,381	8,785	7,359	10,394	10,394	1.2%
Free Cash Flow per share		\$16.76	\$14.63	\$16.24	\$13.68	\$19.21	\$19.21	3.2%
Profitability								
Operating Margin		35.9%	35.2%	36.3%	28.0%	21.7%	21.7%	-11.0%
Return on Assets		11.8%	9.5%	10.4%	8.3%	4.3%	4.3%	-20.8%
Return on Equity		77.2%	88.0%	179.0%	107.8%	69.6%	69.6%	-2.4%
Return on Invested Capital		20.5%	16.9%	18.9%	16.2%	10.1%	10.1%	-15.2%
Dividends								
Dividends Per Share		\$6.40	\$7.04	\$7.76	\$8.52	\$9.00	\$9.52	9.6%
Dividend Yield		3.1%	3.5%	3.2%	3.1%	3.7%	3.4%	2.4%
Dividend Growth		-	10.0%	10.2%	9.8%	5.6%	10.2%	0.6%
Dividend Coverage		1.9x	1.5x	1.6x	1.5x	0.8x	0.8x	-17.5%


VALUATION & PROFITABILITY HISTORY

Date →		TTM	1 Yr Ago	2 Yrs. Ago	3 Yrs. Ago	4 Yrs. Ago
Price / Earnings		37.2	21.6	20.2	24.5	20.9
Price / Cash Flow		13.2	17.1	13.6	15.6	14.5
Price / Book		25.6	23.2	35.8	20.1	15.7
Price / Tangible B...		-	-	-	-	-
Price / Sales		4.6	5.1	5.0	5.6	6.0
EV / EBITDA		14.9	16.8	11.3	14.4	13.4
Forward Dividend...		3.4%	3.3%	3.5%	3.1%	2.7%
Shareholder Yield		3.5%	3.3%	3.5%	10.9%	5.0%
Gross Margin		61.5%	66.4%	74.9%	75.2%	75.6%
Net Margin		12.2%	12.7%	30.2%	21.8%	28.2%
Return on Assets		4.3%	4.2%	12.3%	9.2%	11.2%
Return on Equity		69.6%	74.9%	148.0%	624.8%	75.9%
ROIC		10.1%	10.0%	14.3%	18.4%	19.7%

WARNINGS

Name	Severity	Details
GAAP Earnings vs. Pro Forma	Medium 	Official EPS: \$1.16; Announced EPS: \$5.31

The GAAP compliant earnings that the company filed with the SEC are less than the pro-forma earnings they announced to the press. Pro-forma earnings can exclude special one-time charges but some distressed companies post these "one-time" charges quarter after quarter.

Downward EPS Revisions	Low 	Net EPS Rev. Cur. Qtr.: -7
------------------------	---	----------------------------

Analyst estimates for the next quarter have been revised down. Check for recent news stories about why the future outlook is darker.

REPORT TIPS

Metric Definitions

Metric descriptions are available at stockrover.com/help/metrics/metric-overview

Quantitative Scores

Our scores analytics is to offer our concise analysis of a stock in powerful, but easy to digest format. Each of the composite score metrics are designed to use the best available accounting practices as well as source data from SEC filings. The scores are computed for a company vs. the market as a whole.

Fair Value

Fair value performs a forecasted discounted cash flow analysis of a company to determine the company's intrinsic value based on the expected future cash flows the company will produce. It basically determines what a company is worth based on how much cash flow it is expected to generate for you in the future, taking into account the time value of money and the predictability of those forecasted cash flows.

Peers

Peer ratings are computed from ranking companies in the same

DISCLAIMER

Financial Statements and Historical Prices Provided by Morningstar. © 2025 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Stock Rover and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely.

The information provided does not constitute investment advice, nor does it constitute a recommendation to buy or sell any security. Stock Rover LLC and its content providers are not responsible for any losses resulting from trading decisions arising from any use of this information. Past performance is no guarantee of future results.

The information provided is as of the date written and is subject to change without notice

Additional data provided by [Zacks](#), [Intrinio](#), [Quandl](#), [Yodlee](#), [IEX Cloud](#)